PD-Rx Pharmaceuticals, Inc. (PDRX)
OTCMKTS · Delayed Price · Currency is USD
3.350
0.00 (0.00%)
At close: May 12, 2026
PD-Rx Pharmaceuticals Balance Sheet
Financials in millions USD. Fiscal year is July - June.
Millions USD. Fiscal year is Jul - Jun.
Assets
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 | Jun '21 Jun 30, 2021 |
Cash & Equivalents | 6.17 | 5.4 | 6.83 | 5.47 | 2.9 |
Cash & Short-Term Investments | 6.17 | 5.4 | 6.83 | 5.47 | 2.9 |
Cash Growth | 14.11% | -20.93% | 24.87% | 88.38% | -15.96% |
Receivables | 2.09 | 3.18 | 2.38 | 4.46 | 3.89 |
Inventory | 1.79 | 2.23 | 1.64 | 1.84 | 2.65 |
Other Current Assets | 0.56 | 0.53 | 0.54 | 0.22 | 0.55 |
Total Current Assets | 10.62 | 11.35 | 11.39 | 11.98 | 10 |
Property, Plant & Equipment | 1.28 | 1.44 | 1.52 | 1.24 | 0.83 |
Long-Term Deferred Tax Assets | 0.02 | - | 0.03 | - | 0.07 |
Total Assets | 11.91 | 12.78 | 12.95 | 13.22 | 10.9 |
Liabilities
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 | Jun '21 Jun 30, 2021 |
Accounts Payable | 0.83 | 1.52 | 0.99 | 1.16 | 1.65 |
Accrued Expenses | 0.84 | 0.76 | 0.7 | 0.7 | 0.77 |
Total Current Liabilities | 1.67 | 2.28 | 1.7 | 1.86 | 2.42 |
Long-Term Deferred Tax Liabilities | - | 0 | - | 0.01 | - |
Total Liabilities | 1.67 | 2.29 | 1.7 | 1.87 | 2.42 |
Shareholders' Equity
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 | Jun '21 Jun 30, 2021 |
Common Stock | 0.02 | 0.02 | 0.02 | 0.02 | 0.02 |
Additional Paid-In Capital | 1.34 | 1.34 | 1.34 | 1.34 | 1.34 |
Retained Earnings | 9.28 | 9.54 | 10.29 | 10.39 | 7.36 |
Treasury Stock | -0.41 | -0.41 | -0.41 | -0.41 | -0.24 |
Shareholders' Equity | 10.24 | 10.5 | 11.25 | 11.35 | 8.48 |
Total Liabilities & Equity | 11.91 | 12.78 | 12.95 | 13.22 | 10.9 |
Additional Metrics
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 | Jun '21 Jun 30, 2021 |
Net Cash (Debt) | 6.17 | 5.4 | 6.83 | 5.47 | 2.9 |
Net Cash Growth | 14.11% | -20.93% | 24.87% | 88.38% | 15.14% |
Net Cash Per Share | 3.83 | 3.30 | 4.18 | 3.30 | 1.69 |
Filing Date Shares Outstanding | 1.64 | 1.64 | 1.64 | 1.65 | 1.72 |
Total Common Shares Outstanding | 1.64 | 1.64 | 1.64 | 1.65 | 1.72 |
Working Capital | 8.94 | 9.06 | 9.7 | 10.12 | 7.58 |
Book Value Per Share | 6.23 | 6.38 | 6.84 | 6.90 | 4.95 |
Tangible Book Value | 10.24 | 10.5 | 11.25 | 11.35 | 8.48 |
Tangible Book Value Per Share | 6.23 | 6.38 | 6.84 | 6.90 | 4.95 |
Land | 0.16 | 0.16 | 0.16 | 0.16 | 0.16 |
Buildings | 1.44 | 1.44 | 1.42 | 1.08 | 0.96 |
Machinery | 1.96 | 2.04 | 2.05 | 1.98 | 1.65 |